Drug Combinations for Colon Cancer Prevention and Therapy

Back to all technologies
Download as PDF
Researchers at Purdue University have developed a colon cancer prevention strategy that uses a combination of 5-LOX inhibitors and aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs). Aspirin and other NSAIDs are commonly used as cancer preventative agents as they inhibit COX proteins, one of the primary promoters of inflammation and cancer progression. However, studies have suggested that long term COX inhibition can lead to gastrointestinal side effects and alternative metabolism of COX substrates via the 5-LOX protein pathway. The latter is problematic, because 5-LOX is also commonly overexpressed in cancers. The Researchers' approach inhibits both COX and 5-LOX to synergistically decrease cancer cell viability. In mice, tumor growth was inhibited, and a side effect of aspirin was alleviated. This technology minimizes side effects of using NSAIDs alone, shows efficacy in cellular and mouse models of colon cancer, and may also prevent cancers outside of the colon.

-Synergistic anti-cancer effects
-Decreased inflammation versus NSAID only treatment
-Minimization of Side Effects Associated with NSAIDs

Potential Applications
-Colon cancer preventative treatment option
Nov 23, 2021
Utility Patent
United States

Jan 6, 2021
United States

Nov 25, 2020
Provisional-Gov. Funding
United States
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org